A Study to Evaluate the Safety, Tolerability, and Immunogenicity of SARS-CoV-2 Variant (COVID-19 Omicron) mRNA Vaccine (Phase 1)

• ClinicalTrials.gov Identifier: NCT05433194
• Recruitment Status: Active, not recruiting
• First Posted: June 27, 2022
• Last Update Posted: February 8, 2023
• Sponsor: Suzhou Abogen Biosciences Co., Ltd.
• Information provided by (Responsible Party): Suzhou Abogen Biosciences Co., Ltd.

Study Description

Brief Summary:

A Phase I clinical study to evaluate the safety, tolerability, and immunogenicity of SARS-CoV-2 variant (Omicron) mRNA vaccine which is used to prevent COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

Condition or disease	Intervention/treatment	Phase
COVID-19	Biological: ABO1009-DP	Phase 1

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 48 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Intervention Model Description: Phase I: single-arm Phase I: 48 subjects are planned to be enrolled to receive ABO1009-DP in the test group.
• Masking: None (Open Label)
• Masking Description: Phase I: Open-label
• Primary Purpose: Prevention
• Official Title: A Phase I/II Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of SARS-CoV-2 Variant (Omicron) mRNA Vaccine (ABO1009-DP) for Sequential Immunization in the Population Aged 18 Years and Older Who Have Completed the Full Vaccination
• Actual Study Start Date: August 22, 2022
• Actual Primary Completion Date: September 26, 2022
• Estimated Study Completion Date: August 25, 2023

Arms and Interventions

Arm	Intervention/treatment
Experimental: Phase I Test group 1: ABO1009-DP; Intramuscularly injecting 15 μg of ABO1009-DP into lateral deltoid region of the upper arm of subjects on D0.	Biological: ABO1009-DP; Vaccine

Outcome Measures

Primary Outcome Measures :

1. Phase I: Incidence of solicited adverse events (AEs) [ Time Frame: 0 to 7 days after vaccination with one dose of investigational product. ]
   Solicited adverse events (AEs) 0 to 7 days after vaccination with one dose of investigational product.
2. Phase I: Incidence of unsolicited adverse events (AEs) [ Time Frame: 0 to 28 days after vaccination with one dose of investigational product. ]
   unsolicited adverse events (AEs) 0 to 28 days after vaccination with one dose of investigational product.
3. Phase I: Adverse reactions/events related to blood chemistry, blood routine, blood coagulation function and urinalysis indicators 4 days after vaccination with one dose of investigational product. [ Time Frame: 4 days after vaccination with one dose of investigational product. ]
   Adverse reactions/events related to blood biochemistry, blood routine, blood coagulation function, and urinalysis indicators 4 days after vaccination with one dose of investigational product.

Secondary Outcome Measures :

1. Phase I: Level of S-RBD-specific IgG antibody, titer of neutralizing antibodies, and the number of T cells [ Time Frame: Before Vaccination and 14 Days after Vaccination ]
   Collect venous blood to get data such as S-RBD-specific IgG antibody level and neutralizing antibodies and number of T cells to evaluate the immunogenicity of ABO1009-DP against SARS CoV-2 Omicron variant.
2. Phase I: Incidence of SAEs, AESIs, MAAEs [ Time Frame: one dose of investigational vaccine within 12 months. ]
   Serious adverse events (SAEs), adverse events of special interest (AESIs), and other medically attended adverse events (MAAEs) after vaccination with one dose of investigational vaccine within 12 months.

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: Yes

Criteria

Inclusion Criteria:

• The subjects must meet all of the following inclusion criteria (Phase I):

  1. Voluntarily sign the ICF approved by the Ethics Committee before any study procedure and agree to participate in the study.
  2. Healthy male or female able to provide legal identity certificate and aged 18 years and older when signing the ICF.
  3. Subjects who are fully vaccinated either by 2 or 3 doses. The 2-dose immunization or the second dose of the 3-dose immunization should be from 6 to 24 months before administration of the investigational vaccine. The third dose should be >3 months before administration of the investigational vaccine.
  4. Be able to communicate well with the investigator, and to understand and comply with the requirements of this clinical trial.
  5. Males and females with childbearing potential voluntarily take effective contraceptive methods from signing ICF to 3 months after completing the vaccination, including sexual abstinence or effective contraceptive measures (e.g., intrauterine or implanted contraceptive device, oral contraceptives, injected or implanted contraceptives, sustained-release topical contraceptives, intrauterine device [IUD], condoms [male], diaphragm, and cervical cap).

Exclusion Criteria:

• Phase I:

Subjects should not participate in this clinical study if any of the following criteria is met:

1. Positive SARS-CoV-2 reverse transcription-polymerase chain reaction (RT-PCR) test at screening.
2. Prior medical history of severe acute respiratory syndrome (SARS), middle east respiratory syndrome (MERS), and other human coronavirus infections or diseases.

3. Fever (axillary temperature or equivalent ≥ 37.3℃*) on the day of vaccination with this investigational vaccine or within recent 72 hours.

   * Tympanic Temperature °C - 0.56°C = Axillary Equivalent in °C

4. Abnormal vital signs (pulse < 60 bpm or > 100 bpm, systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg when keeping awake) with clinical relevance.
5. Abnormal laboratory values and with clinical significance at the investigator's discretion at screening.
6. Do not remain overall healthy (i.e., has medically deteriorated significantly since receiving the two-dose vaccination, is anticipated to have fatal outcome of uncontrolled diseases within 12 months, and is not able to provide blood as specified by the trial with anticipated, deleterious medical consequences) in the clinical judgment of the investigator based on medical history and physical examination.
7. Pregnant or lactating women, or those who plan to donate sperm or egg during the trial.
8. Prior history of allergic reaction or anaphylaxis to any vaccine or its excipients, e.g., hypersensitivity, urticaria, serious eczema, dyspnea, laryngeal edema, and angioedema etc.
9. Prior use of any other vaccine within 28 days before screening or planning to use any vaccine other than this investigational vaccine during the study period.
10. Participation in the studies of any other interventional device or drug within 30 days before the screening, or current treatment with other investigational drug(s) or within 5 half-lives after taking the last dose of the study drug.
11. Hereditary hemorrhagic tendency or coagulation dysfunction (e.g., cytokine defects, coagulation disorders or platelet disorder), or a history of serious bleeding, or a history of massive bleeding after intramuscular injection or intravenous puncture or ecchymosis.
12. Known medical history or diagnosis confirming that subjects have diseases affecting immune system function, including cancer (except skin basal cell carcinoma), congenital or acquired immunodeficiency (e.g., infection with human immunodeficiency virus [HIV]), and uncontrolled autoimmune disease.
13. Serious or uncontrolled respiratory system disorders, cardiovascular disorders, nervous system disorders, blood and lymphatic system disorders, liver and kidney disorders, metabolism and skeletal disorders, etc. influencing study results evaluation at the investigator's discretion.
14. Asplenia or functional asplenia.
15. Long-term use (continuous use ≥14 days) of immunosuppressants or other immunomodulators (e.g., glucocorticoids: prednisone or similar drugs) within 6 months prior to administration of this investigational vaccine, except for topical medications (e.g., ointments, eye drops, inhalants, or nasal sprays). And the topical medications should not exceed the recommended dose in the labels for use or induce any signs of systemic exposure.
16. Having received immunoglobulins and/or blood products within 3 months prior to administration of this investigational vaccine.
17. Suspected or known alcohol dependency or drug abuse, which may affect safety evaluation or subject's compliance at the investigator's discretion.
18. Planning to permanently move from the local area before study completion or leave the local area for a long time during the period of study visits.
19. Currently receiving antituberculosis treatment.
20. Staff of study site, sponsor and contract research organization (CRO) taking part in the study.
21. Other conditions that the investigators consider unsuitable for this study.

Contacts and Locations

Locations

United Arab Emirates

AL Kuwait Hospital

Dubai, United Arab Emirates

Sponsors and Collaborators

Suzhou Abogen Biosciences Co., Ltd.

More Information

• Responsible Party: Suzhou Abogen Biosciences Co., Ltd.
• ClinicalTrials.gov Identifier: NCT05433194
• Other Study ID Numbers: ABO1009-DP-005
• First Posted: June 27, 2022
• Last Update Posted: February 8, 2023
• Last Verified: August 2022

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Suzhou Abogen Biosciences Co., Ltd.:

Omicron; COVID-19

Additional relevant MeSH terms:

COVID-19; Pneumonia, Viral; Pneumonia; Respiratory Tract Infections; Infections; Virus Diseases; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Lung Diseases; Respiratory Tract Diseases